All Eyes on ISIS Pharmaceuticals, Inc.'s Pipeline
Isis has an approved drug, but earnings should be all about the pipeline of 32 drugs.
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Alnylam's third-quarter earnings call was all about the pipeline data.
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Bl
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Momenta Pharmaceuticals, Inc. Pushes Forward
With just $4.7 million from sales of enoxaparin in the third quarter, investors have to be focused on the pipeline.
Regeneron Pharmaceuticals Inc. Earnings: Eylea's Roller-Coaster Ride
Regeneron Pharmaceuticals guides for 2014 U.S. Eylea sales toward the low end of previous guidance, causing shares to slip.